NCT04754035View on ClinicalTrials.gov

Clinical Study With Ibrutinib and Venetoclax for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

31

Participants

Timeline

Start Date

November 8, 2017

Primary Completion Date

July 31, 2018

Study Completion Date

September 1, 2025

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG

Venetoclax

venetoclax 20 mg, 50 mg, 100 mg

DRUG

Imbruvica Oral Product

Imbruvica 140 mg

Trial Locations (1)

20132

Ospedale San Raffaele, Milan

All Listed Sponsors

lead

Paolo Ghia

OTHER